NEW YORK (GenomeWeb News) – The molecular diagnostics firm PrimeraDx has closed $20 million in a Series C financing round through investments from new and existing investors.
This round of investments was led by CHL Medical Partners and included Abingworth, InterWest Partners, Malaysian Technology Development, MPM Capital, Burrill & Company, and the Invus Group.
PrimeraDx CEO and President Martin Verhoef said in a statement that the company will use the funding to continue commercializing its technology, including advancing its regulatory strategy and broadening a quantitative, multiplexed assay menu to run on its ICEPlex system.